Printer Friendly

TELIOS INITIATES CLINICAL TRIALS FOR ADDITIONAL DERMAL WOUND HEALING APPLICATIONS; INTERIM ANALYSIS REVEALS ADEQUATE SAMPLE SIZE

TELIOS INITIATES CLINICAL TRIALS FOR ADDITIONAL DERMAL WOUND HEALING
 APPLICATIONS; INTERIM ANALYSIS REVEALS ADEQUATE SAMPLE SIZE
 SAN DIEGO, April 29 /PRNewswire/ -- Telios Pharmaceuticals Inc. (NASDAQ: TLIO) announced today that it has initiated multi-center clinical trials of Telio-Derm(TM), the Company's RGD peptide wound healing product, for two additional applications. Telio-Derm will be tested for improved healing of skin graft donor sites in elderly burn patients and scalds (second degree burns) in children.
 Pivotal multi-center clinical trials of Telio-Derm are in progress at over 35 medical institutions throughout the United States to study improved healing of chronic dermal ulcers including venous stasis, diabetic and sickle-cell disease related ulcers. Telios also announced that it has conducted an analysis of patient enrollment in the venous stasis ulcer study to determine whether the total number of patients to be enrolled in the study will be sufficient for statistical purposes. Based upon this analysis, Telios has decided to complete the study with no changes in the planned patient enrollment. The Company confirmed its previous expectation that final study results will not be available to it until late 1992.
 Telios is developing a new class of therapeutic products based upon research into the role of the extracellular matrix. The Company is applying its proprietary technology to develop products for the treatment of severe and chronic dermal wounds, ophthalmic wounds, fibrotic disease, cardiovascular disease and osteoporosis.
 -0- 4/29/92
 /CONTACT: Robert J. Erickson, Ph.D., president and CEO of Telios Pharmaceuticals, 619-622-2615/
 (TLIO) CO: Telios Pharmacueticals Inc. ST: California IN: MTC SU:


KJ-JL -- SD008 -- 4679 04/29/92 19:23 EDT
COPYRIGHT 1992 PR Newswire Association LLC
No portion of this article can be reproduced without the express written permission from the copyright holder.
Copyright 1992 Gale, Cengage Learning. All rights reserved.

Article Details
Printer friendly Cite/link Email Feedback
Publication:PR Newswire
Date:Apr 29, 1992
Words:265
Previous Article:DOE BEGINS COMPETITION FOR OPERATOR OF PETROLEUM RESEARCH FACILITY IN OKLAHOMA
Next Article:SHAREHOLDER LAWSUIT INITIATED AGAINST CARENETWORK


Related Articles
TELIOS PHARMACEUTICALS EXPANDS TELIO-DERM(TM) CLINICAL TRIALS Wound Healing Product Shows Encouraging Results
TELIOS PHARMACEUTICALS INC. SELLS 2.5 MILLION SHARES OF COMMON STOCK IN INITIAL PUBLIC OFFERING
TELIOS ANNOUNCES FIRST QUARTER 1992 RESULTS
TELIOS ANNOUNCES SECOND QUARTER 1992 RESULTS
TELIOS ANNOUNCES THIRD QUARTER 1992 RESULTS
TELIOS ANNOUNCES NORSK HYDRO DECISION
TELIOS SUBMITS PMA FOR TELIO-DERM(R) WOUND HEALING AGENT
TELIOS ANNOUNCES CLINICAL RESULTS OF SICKLE-CELL LEG ULCER STUDY

Terms of use | Copyright © 2017 Farlex, Inc. | Feedback | For webmasters